Price$25.11+0.14 (+0.56%)
01:30 PM07:45 PM
News · 26 weeks58+33%
2025-10-262026-04-19
Mix2290d
- Insider9(41%)
- SEC Filings7(32%)
- Other3(14%)
- Earnings2(9%)
- Leadership1(5%)
Latest news
25 items- INSIDERSEC Form 3 filed by new insider Martin William E. Iii3 - Azenta, Inc. (0000933974) (Issuer)
- SECAzenta Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Azenta, Inc. (0000933974) (Filer)
- PRAzenta Life Sciences Announces Leadership Transition to Accelerate Gene Synthesis Strategy and Multiomics ExecutionBURLINGTON, Mass., April 7, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced the appointment of Trey Martin as President of its Multiomics business, effective April 6, 2026. In this role, Mr. Martin will lead the Multiomics organization and report to John Marotta, Azenta's President and Chief Executive Officer.This appointment is aimed at accelerating execution of Azenta's Multiomics long-range plan, outlined at its December 2025 Investor Day, with a continued focus on scaling global synthesis capabilities, strengthening operational excellence, enhancing commercial discipline, and driving profitable growth across the integrated Multiomics platform to support broader market ado
- SECAzenta Inc. filed SEC Form 8-K: Other Events8-K - Azenta, Inc. (0000933974) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Azenta Inc.SCHEDULE 13G/A - Azenta, Inc. (0000933974) (Subject)
- SECAzenta Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Azenta, Inc. (0000933974) (Filer)
- PRAzenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository CapabilitiesBURLINGTON, Mass., March 4, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA), a leading provider of life science solutions, today announced that its wholly owned subsidiary, Azenta UK Ltd, has acquired UK Biocentre Limited, a leading provider of sample management, sample storage and high-throughput sample processing services in the United Kingdom. The total consideration was GBP 20.5 million, net of cash and inclusive of up to GBP 1.8 million in contingent consideration upon the completion of certain milestones. The acquisition strengthens Azenta's ability to deliver end-to-end l
- PRAzenta to Participate in Raymond James 47th Annual Institutional Investor ConferenceBURLINGTON, Mass., Feb. 24, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Company management will participate in Raymond James 47th Annual Institutional Investor Conference, on Tuesday March 3rd, 2026, which includes a presentation beginning at 4:00 pm ET. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event.About Azenta Life SciencesAzenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta p
- PRAzenta Life Sciences and Frontier Space Announce Strategic Partnership to Advance Space-Based Life Sciences Research InfrastructureBURLINGTON, Mass., Feb. 9, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced a strategic partnership with Frontier Space, a pioneer in commercial space-based research systems, to conduct cutting-edge scientific experiments in space. This collaboration aims to harness the unique benefits of the microgravity environment to accelerate discovery and innovation in life sciences, including participation in the recently launched EGGS-2 (Early Gen micro-Gravity Service) mission, developed in collaboration with Orbital Paradigm. The mission was intended to test and advance the performance of Frontier's SpaceLab Mk 2 research platform under real launch and spaceflight conditions. This co
- INSIDERAmendment: SEC Form 4 filed by Director Cornog William L4/A - Azenta, Inc. (0000933974) (Issuer)
- INSIDERDirector Nova Tina Susan was granted 5,663 units of Common, increasing direct ownership by 56% to 15,772 units (SEC Form 4)4 - Azenta, Inc. (0000933974) (Issuer)
- INSIDERSEC Form 4 filed by Director Cornog William L4 - Azenta, Inc. (0000933974) (Issuer)
- INSIDERSEC Form 4 filed by Director Madaus Martin D4 - Azenta, Inc. (0000933974) (Issuer)
- INSIDERDirector Doshi Dipal was granted 5,663 units of Common, increasing direct ownership by 140% to 9,703 units (SEC Form 4)4 - Azenta, Inc. (0000933974) (Issuer)
- INSIDERDirector Casal Frank was granted 7,243 units of Common, increasing direct ownership by 50% to 21,803 units (SEC Form 4)4 - Azenta, Inc. (0000933974) (Issuer)
- INSIDERDirector Mclaughlin Erica was granted 5,663 units of Common, increasing direct ownership by 34% to 22,521 units (SEC Form 4)4 - Azenta, Inc. (0000933974) (Issuer)
- INSIDERSEC Form 4 filed by Director Davis Robyn C4 - Azenta, Inc. (0000933974) (Issuer)
- SECSEC Form 10-Q filed by Azenta Inc.10-Q - Azenta, Inc. (0000933974) (Filer)
- SECAzenta Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Azenta, Inc. (0000933974) (Filer)
- PRAzenta Reports First Quarter Results for Fiscal 2026, Ended December 31, 2025BURLINGTON, Mass., Feb. 4, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today reported financial results for the first quarter ended December 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale and the entry into a definitive agreement to sell the business, which is expected to close on or before March 31, 2026. Quarter Ended Dollars in millions, except per share data December 31, September 30, December31, Change 2025 2025 2024 (1) Prior Qtr Prior Yr. Revenue from Continuing Operations $ 149 $ 159 $ 147 (7) % 1 % Organ
- SECAzenta Inc. filed SEC Form 8-K: Leadership Update8-K - Azenta, Inc. (0000933974) (Filer)
- SECAzenta Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Azenta, Inc. (0000933974) (Filer)
- PRAzenta Announces Fiscal 2026 First Quarter Conference Call and WebcastBURLINGTON, Mass., Jan. 21, 2026 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) will announce fiscal first quarter 2026 earnings which ended on December 31, 2025, on Wednesday, February 4, 2026, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Wednesday, February 4, 2026, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay will be available beginning at 8:30 a.m. ET on February 5, 2026. About Azenta Life SciencesAzenta, Inc. (NASDAQ:AZTA) is a leading provider of life sciences solutions worldwide
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Azenta Inc.SCHEDULE 13G/A - Azenta, Inc. (0000933974) (Subject)
- ANALYSTAzenta upgraded by Evercore ISI with a new price targetEvercore ISI upgraded Azenta from In-line to Outperform and set a new price target of $50.00